Patients’ expectations ‘unfairly raised’ over medicinal cannabis use

Support us and go ad-free

Doctors are “handling the backlash” around the use of medicinal cannabis after patients’ expectations were unfairly raised by poor Government communication, a Parliamentary report has said.

Relationships between doctors and patients expecting ready access to prescriptions have worsened, according to the House of Commons health and social care committee report.

Poor communication from the Home Office and Department of Health and Social Care raised expectations over the availability of medicinal cannabis, the committee found.

The subsequent need to “clarify misconceptions” has led to “public mistrust in the regulatory system and angry patients”, it added.

The regulation of medicinal cannabis was reviewed in November 2018 after the chief medical officer found evidence, though contested, for its use in certain conditions.

It was rescheduled, allowing specialist doctors to legally prescribe products and research to be carried out into them.

Only one cannabis-based product for medicinal use (CBPM) is licensed in the UK but is not regularly prescribed on the NHS because it has not been deemed cost effective.

Doctors can still prescribe unlicensed products if they believe it is medically appropriate, but a lack of research and evidence on the effects of these products means many are reluctant to take personal responsibility.

The report said: “Once it became apparent that there was a degree of misunderstanding about the rescheduling, it would have been feasible for the Government to step in to clarify the situation.

“Whilst clinicians have been issued guidance in the interim by their professional bodies, the Government has done little to correct the widespread misconceptions regarding CBPMs.

“Patients have had their expectations raised unfairly and doctors are handling the backlash of poor Government handling.”

The committee is recommending that the Government and NHS England form a communications plan “to relay clear information to patients and the wider public about the availability of CBPMs and the need for further research”.

It also urged the Government to stop seizing medicinal cannabis brought into the UK from abroad and to explore the potential for medicinal cannabis to treat epileptic children with a “greater sense of urgency”.

The report said: “We are deeply sympathetic to families who want to be able to use medicinal cannabis to treat their children and who have seen individual benefit but are unable to obtain the product here in the UK.

“There needs to be a sense of urgency to explore the potential of medicinal cannabis in these conditions so that there is a robust research base on which to base future clinical decisions.

“We also call on the Government to desist from confiscating prescribed medicinal cannabis obtained overseas under specialist supervision.”

The committee said research proposals in this area should be prioritised and all children with severe and intractable epilepsy should have access to clinical trials.

One of the barriers to research is that some companies are not always willing to provide their product for trial, the report found.

The committee is asking the Department of Health to “name and shame” pharmaceutical companies which are not making their medicinal cannabis products available for research.

And it should secure long-term international deals to ensure a consistent supply of CBPMs so patients do not experience delays in getting prescriptions.

Support us and go ad-free

We need your help to keep speaking the truth

Every story that you have come to us with; each injustice you have asked us to investigate; every campaign we have fought; each of your unheard voices we amplified; we do this for you. We are making a difference on your behalf.

Our fight is your fight. You’ve supported our collective struggle every time you gave us a like; and every time you shared our work across social media. Now we need you to support us with a monthly donation.

We have published nearly 2,000 articles and over 50 films in 2021. And we want to do this and more in 2022 but we don’t have enough money to go on at this pace. So, if you value our work and want us to continue then please join us and be part of The Canary family.

In return, you get:

* Advert free reading experience
* Quarterly group video call with the Editor-in-Chief
* Behind the scenes monthly e-newsletter
* 20% discount in our shop

Almost all of our spending goes to the people who make The Canary’s content. So your contribution directly supports our writers and enables us to continue to do what we do: speaking truth, powered by you. We have weathered many attempts to shut us down and silence our vital opposition to an increasingly fascist government and right-wing mainstream media.

With your help we can continue:

* Holding political and state power to account
* Advocating for the people the system marginalises
* Being a media outlet that upholds the highest standards
* Campaigning on the issues others won’t
* Putting your lives central to everything we do

We are a drop of truth in an ocean of deceit. But we can’t do this without your support. So please, can you help us continue the fight?

The Canary Support us